Jim Cramer: Vertex Pharmaceuticals Incorporated (VRTX), Gilead Sciences, Inc (GILD), Celgene Corporation (CELG) Among the Hottest Stocks

1

For the 23rd time in this year, the Dow Jones Industrial Average index made to the highest records yesterday, adding 129 points. The averages are jumping to new heights. The market trends are getting stronger and stronger these days in multifarious domains and the investors are lurking to cease multiple options they have to get the most out of this market hike. To review the most favorable market themes for investors and to shed some light on the main hot options for the market enthusiasts, Jim Cramer on CNBC analyzed in detail and said that there are various reasons of the record high stats of the Dow.

vertex pharma

Cramer made the big deduction from these average hikes and made a perdition that the next quarter’s profits will be better than expected. The first quarter of the year 2014 has already been healthy and positive for the investors who had to face immense problems in 2013. To give the review of the market themes so that people can cease the investing opportunities, Cramer started off with the hottest market domain of today, the biotech.

The first is the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) which is doing pretty well and expected to achieve new milestones in the second quarter. According to Cramer, this was mainly because of the remarkable breakthrough of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in countering the terrible disease of cystic fibrosis with its drug called Kalydeco. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to top the market.

Then comes Gilead Sciences, Inc.(NASDAQ:GILD) which is in the news and stock trends. The reason behind this was the successful new drug by Gilead Sciences, Inc.(NASDAQ:GILD) for Hepatitis C. This drug can really give a breakthrough to Gilead Sciences, Inc.(NASDAQ:GILD) in the coming quarter.

Celgene Corporation (NASDAQ:CELG) is another biopharmaceutical company that must be under the focus lens of investors. Celgene Corporation (NASDAQ:CELG) is getting famous because of its cheapest drug rates as pricing is a big factor to look for in the Biotech sector. Cramer thinks that Celgene Corporation (NASDAQ:CELG) has great chances to succeed in the market in the coming days. Cramer labelled Celgene as the world’s cheapest drug company.

Then there is Celgene, which soared today on a report from BMO, saying the company is a lot more than just revilement, something I’ve tried to tell you repeatedly about this charitable trust name which is the cheapest big drug cap company in the universe,” said Cramer.

Cramer thinks that the rebound of Biotech stocks are related to the return of the growth of many other parts of the market

Disclosure: None

Share.

1 Comment

  1. How can VRTX have a market cap of nearly $23B with a presently ACTUAL revenue stream of $0.5B, debt of $0.5B and a yet commercially unproven drug(s) in a 30,000 patient market…? This is wonderful for CF patients–truly it is–but from a cold economic perspective it makes about as much sense as, well, TWTR’s (just slightly greater) market cap. Hmmmmmmm…..

Leave A Reply